Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06626620

Enrollment

120

Registered

2024-10-04

Start date

2024-01-01

Completion date

2024-09-30

Last updated

2024-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Exacerbation of Asthma

Keywords

Asthma, intravenous, magnesium sulfate, terbutaline

Brief summary

This study aimed to fill this gap by comparing the effectiveness of intravenous magnesium sulfate versus terbutaline in children with acute asthma exacerbations, providing evidence-based guidance for clinicians in emergency settings.

Detailed description

Despite the established roles of both magnesium sulfate and terbutaline in the management of severe asthma exacerbations, there is limited comparative data on their efficacy and safety in the pediatric population. Understanding the relative benefits and risks of these therapies is crucial for optimizing treatment strategies and improving patient outcomes.

Interventions

DRUGMagnesium Sulphate infusion

Received IV magnesium sulfate (50 mg/kg up to a maximum dose of 2 g) administered over 20 minutes

DRUGTerbutaline Infusion

Received IV terbutaline (10 mcg/kg bolus followed by a continuous infusion of 0.4 mcg/kg/min) for up to 4 hours

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

5 Years to 12 Years

Healthy volunteers

Inclusion criteria

* Known cases of asthma * Minimum duration of asthma as 6 months * Presenting with acute exacerbation of asthma * Requiring emergency treatment.

Exclusion criteria

* Children having chronic respiratory diseases (cystic fibrosis, bronchopuonary dysplasia) * Children with cardiac diseases * Children who were hospitalized in the past 2-weeks due to any reasons * Children using oral or intravenous corticosteroids or other systemic medications * Children who were unable to undergo PEFR measurements due to any reasons

Design outcomes

Primary

Measure	Time frame	Description
Post-treatment PEFR	4 hours	Post-treatment, children response to treatment was measured by noting PEFR

Secondary

Measure	Time frame	Description
Oxygen Saturation	4 hours	Post-treatment, oxygen saturation was measured using Spirometry
Heart Rate	4-hours	Post-treatment, heart rate was measured
Respiratory rate	4 hours	Post-treatment, heart rate was measured.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026